IP Library Granted Patent US 10,857,191
Granted Patent B2
US 10,857,191 · App. 15/766,076 · Granted Dec 8, 2020

Sandalwood oil and its uses related to oral mucositis

Inventors: Corey Levenson (San Antonio, TX); Paul Castella (San Antonio, TX); Ian Clements (San Antonio, TX)
Assignee: SANTALIS PHARMACEUTICALS, INC.
A61K36/185A61K8/922A61K9/006A61K45/06A61K47/10A61K47/26A61Q11/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,857,191
App. No.
15/766,076
Granted
Dec 8, 2020
Kind
B2
Abstract

Provided herein are methods of using therapeutically effective compositions of sandalwood oil to treat oral mucositis.

Claims (10)

1. A method of treating oral mucositis in a subject, said method comprising administering to the subject in need thereof, a composition comprising about 0.03% to about 30% sandalwood oil (w/w), wherein the pH of the composition is about 3.5 to about 4.1, wherein the subject has head and neck cancer, and wherein the oral mucositis is caused by radiation therapy and/or chemotherapy.

2. The method of claim 1 , wherein the composition is administered to the subject prior to, concurrently with, or subsequent to radiation therapy and/or chemotherapy.

3. The method of claim 1 , wherein the composition is administered topically to the subject.

4. The method of claim 3 , wherein the composition is administered topically to the mouth and/or throat of the subject.

5. The method of claim 4 , wherein the composition is a mouthwash composition.

6. The method of claim 5 , wherein the mouthwash composition is a non-alcoholic mouthwash composition.

7. The method of claim 1 , wherein the sandalwood oil is from Santalum album or Santalum spicatum or a combination thereof.

8. The method of claim 1 , wherein the composition further comprises a pharmaceutically acceptable carrier.

9. The method of claim 1 , further comprising administering an antifungal composition, an analgesic, and/or an antifibrinolytic agent to the subject.

10. The method of claim 9 , wherein the antifungal composition, the analgesic, and/or the antifibrinolytic agent are administered topically to the subject.

Assignments (2)
SECURITY INTEREST Recorded Oct 23, 2018
From: SANTALIS HEALTHCARE CORPORATION; SANTALIS PHARMACEUTICALS, INC.
To: GLOBAL LOAN AGENCY SERVICES AUSTRALIA NOMINEES PTY LTD
Reel/Frame 047282/0532 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 12, 2018
From: LEVENSON, COREY; CLEMENTS, IAN; CASTELLA, PAUL
To: SANTALIS PHARMACEUTICALS, INC.
Reel/Frame 045528/0612 →
Continuity (2)
Provisional Application 62238449 · Oct 7, 2015
Related Publication 20190209630A1 · Jul 11, 2019